At 8,000p, is FTSE 100 company AstraZeneca a share worth me buying right now?

If the R&D pipeline can keep powering yearly increases in earnings near 26%, as forecast for next year, I reckon AstraZeneca stock could rocket.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Of course, the big news this week from London-listed pharmaceutical giant AstraZeneca (LSE: AZN) is that its AZD1222 vaccine met primary efficacy endpoint in preventing Covid-19.

Hoorah! Now we have three potential mass-market Covid-19 vaccines produced in the Western world – the Pfizer/BioNTech one, the Moderna one, and now the AstraZeneca one developed in collaboration with Oxford University.

Professor Andrew Pollard, chief investigator of the Oxford Vaccine Trial at Oxford, said: “We’ve found that one of our dosing regimens may be around 90% effective.” And that great news puts the vaccine right up there with its competitors’ outcomes.

Why I think AstraZeneca is a share worth buying

However, AstraZeneca’s share price didn’t react much to the news. And chief executive Pascal Soriot shed some light on why that might be. He said in its press release: “The vaccine’s simple supply chain and our no-profit pledge and commitment to broad, equitable and timely access mean it will be affordable and globally available.”

So, that no-profit pledge probably means AstraZeneca will cover its costs developing, producing and distributing the vaccine, but won’t benefit financially from its success beyond that –at least for a while. Indeed, the no-profit pledge is time-limited. And profits will flow to the company from the vaccine after the pandemic ends. Some sources have it the firm could declare the end of the pandemic as early as July 2021.

Even so, AZD1222 Covid-19 vaccine isn’t the only trick in AstraZeneca’s box. The firm’s news feed is vibrant and has been for many months and over recent years. The dark days of patent-expiry headaches and a wilting share price are long gone. Now, the Research & Development (R&D) pipeline is spitting out marketable products at a fast pace. And I think that’s a great reason for buying some of the shares now to tuck away for the long haul.

Indeed, I wish I’d done just that 10 years ago. Then, I was thinking of buying some and when the stock was changing hands near 3,060p. I’m not even going to calculate the percentage capital gain because the thought of the missed opportunity is too painful! But what about now? Could we see a similar rise in the share price over the next decade? I believe it’s possible.

Growth in earnings ahead

City analysts following the firm have pencilled in an increase in earnings near 26% for next year. If the R&D pipeline can keep powering incremental yearly increases in earnings near that level, I reckon the share could rocket over the next 10 years.

Meanwhile, in the short term, we’re seeing a bit of weakness in the share price. And that could be driven by the big rotation from defensive shares like AstraZeneca into cyclical shares that look set to benefit from the retreat of Covid-19.

Indeed, investors can’t have their money everywhere all at once. So they could be selling AstraZeneca shares to buy stocks like Lloyds right now. I’d take a contrarian approach, buy defensives like AstraZeneca, and hold for the long haul.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any share mentioned. The Motley Fool UK has recommended Lloyds Banking Group. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »